NJ S2283

Establishes the Psilocybin Behavioral Health Access and Therapy Pilot Program within the New Jersey Department of Health to advance psilocybin research compliant with FDA and DEA regulations.

Creates the Psychedelic Therapy and Research Advisory Board consisting of 11 members, including the Commissioner of Health, Deputy Commissioner for Public Health Services, and nine public members with expertise in behavioral healthcare, psychedelic clinical trials, and public health policy.

Requires participating hospitals to be selected from three state regions (Northern, Central, and Southern), with community-based organizations partnering with licensed healthcare facilities eligible to participate.

Appropriates $6 million to fund the pilot program, which aims to evaluate whether a comprehensive statewide psilocybin therapy delivery system can be developed in the future.

Targets treatment of behavioral health conditions including substance use disorders, depression, anxiety disorders, and end-of-life psychological distress, building on FDA breakthrough therapy designation for psilocybin in treatment-resistant depression.